Skip directly to page options Skip directly to A-Z link
Volume 29, Number 4—April 2023
Dispatch

Two-Year Cohort Study of SARS-CoV-2, Verona, Italy, 2020‒2022

Zeno Bisoffi1Comments to Author , Nicoletta De Santis1, Chiara Piubelli, Michela Deiana, Francesca Perandin, Pietro Girardi, Luca Heller, Natalia Alba, Carlo Pomari2, and Massimo Guerriero2
Author affiliations: Istituto di Ricovero e Cura a Carattere Scientifico Sacro Cuore Don Calabria Hospital, Verona, Italy (Z. Bisoffi, N. De Santis, C. Piubelli, M. Deiana, F. Perandin, C. Pomari, M. Guerriero); AULDSS 9 Scaliger Regione del Veneto, Verona (P. Girardi, L. Heller, N. Alba)

Main Article

Table

Comparison of antibody test results in 2 field surveys for SARS-CoV-2, Verona, Italy, May 2020 and November 2021

Characteristic
 2021
Negative, no. (%)
 Positive, no. (%)
 Total, no. (%)
 p value
IgG against nucleocapsid
2020 <0.0001
Negative, no. (%) 720 (83.4) 143 (16.6) 863 (100.00)
Positive, no. (%) 17 (50.0) 17 (50.0) 34 (100.0)
Total, no.(%)
 737 (82.2)
 160 (17.8)
 897 (100.0)
IgG against spike protein
2020
Negative, no. (%) 65 (7.6) 796 (92.4) 861 (100.0)
Positive, no. (%) 0 (0) 35 (100.0) 35 (100.0) 0.170*
Total, no. (%) 65 (7.3) 831 (92.7) 896 (100.0)

*By Fisher exact test.

Main Article

1These first authors contributed equally to this article.

2These senior authors contributed equally to this article.

Page created: January 19, 2023
Page updated: March 21, 2023
Page reviewed: March 21, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external